ARTICLE | Clinical News
EC approves Vifor's Veltassa for hyperkalemia
July 28, 2017 6:12 AM UTC
Vifor Pharma Ltd. (SIX:VIFN) said the European Commission approved an MAA for Veltassa patiromer (RLY5016) to treat hyperkalemia in adults, including patients who develop the condition while undergoing renin-angiotensin-aldosterone system (RAAS) inhibitor therapy. Vifor said the application was also approved in Norway, Liechtenstein and Iceland.
The company plans to launch Veltassa in the first Europe territories by year end or early 2018. The drug is also under review in Switzerland and Australia...